View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 4, 2011

Endo Reports Positive Results of Back Pain Drug

Endo Pharmaceuticals has announced the successful clinical results from a Phase II study of axomadol, a drug to treat moderate-to-severe chronic low back pain. The drug was orally administered at doses ranging from 100mg a day to 300mg a day over a four-week period, with a 12-week main

By cms admin

Endo Pharmaceuticals has announced the successful clinical results from a Phase II study of axomadol, a drug to treat moderate-to-severe chronic low back pain.

The drug was orally administered at doses ranging from 100mg a day to 300mg a day over a four-week period, with a 12-week maintenance phase.

The randomised, double blind, placebo-controlled and parallel group study included 236 patients and showed a change in average pain intensity from baseline.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology